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Inherited cutis laxa, or inelastic, sagging skin is a genetic condition of prema-
ture and generalised connective tissue ageing, affecting various elastic compo-
nents of the extracellular matrix. Several cutis laxa syndromes are inborn
errors of metabolism and lead to severe neurological symptoms. In a patient
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with cutis laxa, a choreoathetoid movement disorder, dysmorphic features and
intellectual disability we performed exome sequencing to elucidate the under-
lying genetic defect. We identified the amino acid substitution R275W in pho-
sphatidylinositol 4-kinase type IIα, caused by a homozygous missense
mutation in the PI4K2A gene. We used lipidomics, complexome profiling and
functional studies to measure phosphatidylinositol 4-phosphate synthesis in
the patient and evaluated PI4K2A deficient mice to define a novel metabolic
disorder. The R275W residue, located on the surface of the protein, is involved
in forming electrostatic interactions with the membrane. The catalytic activity
of PI4K2A in patient fibroblasts was severely reduced and lipid mass spectrom-
etry showed that particular acyl-chain pools of PI4P and PI(4,5)P2 were
decreased. Phosphoinositide lipids play a major role in intracellular signalling
and trafficking and regulate the balance between proliferation and apoptosis.
Phosphatidylinositol 4-kinases such as PI4K2A mediate the first step in the
main metabolic pathway that generates PI4P, PI(4,5)P2 and PI(3,4,5)P3.
Although neurologic involvement is common, cutis laxa has not been reported
previously in metabolic defects affecting signalling. Here we describe a patient
with a complex neurological phenotype, premature ageing and a mutation in
PI4K2A, illustrating the importance of this enzyme in the generation of inositol
lipids with particular acylation characteristics.
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1 | INTRODUCTION
Phosphoinositide lipids coordinate several crucial cellu-
lar processes, including vesicular trafficking and intra-
cellular signalling.1,2 Rapid changes in specific cellular
pools of phosphoinositide lipids are generated by multi-
ple phosphoinositide kinases, phospholipases and
phosphatases.3
The four isoenzymes that constitute the pho-
sphatidylinositol (PI) 4-kinases (PI4Ks) catalyse the ini-
tial step in the pathways that generates PI(4,5)P2 and
PI(3,4,5)P3 by phosphorylating PI at the D4 position to
produce PI 4-phosphate (PI4P).3,4 The four isoenzymes
are PI4K2A, PI4K2B, PI4KA and PI4KB (Figure 1).
Although the product is always PI4P, the isoforms are
targeted to different organelles and show tissue
FIGURE 1 PI 4-kinases catalyse the ATP-dependent D4 phosphorylation of PI to generate PI4P. PI4K2A is one of the four mammalian
PI 4-kinase isozymes and it localises mainly to the TGN and endosomes. Both PI4K2A and its PI4P product can bind and recruit proteins
required for the formation of trafficking vesicles on intracellular membranes. PI4P can subsequently be phosphorylated by PIP 5-kinases to
form PI(4,5)P2 an important signalling and trafficking molecule. PI(4,5)P2 is in turn a substrate for class I phosphoinositide 3-kinases that
generate PI(3,4,5)P3; however, PI4K2A activity is not thought to be rate limiting for PI(3,4,5)P3 production. Dephosphorylation routes to
form PI and PI4P, and the phosphoinositide phosphatases that can potentially catalyse these reactions have also been included
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specificity.4,5 This study focuses on the PI 4-kinase iso-
form 2-alpha (PI4K2A), encoded by PI4K2A, which func-
tions in endosomal-lysosomal trafficking, endosomal
exocytosis, Akt activation, packaging of von Willebrand
factor in Weibel-Palade bodies, autophagosome:lysosome
fusion and the regulation of sphingomyelin synthesis at
the trans-Golgi network and the trafficking of lysosomal
enzymes, including glucocerebrosidase (GBA), to the
lysosome.6-10 Despite the fact that cellular PI4P levels are
maintained by four different pathways that generate PI
4-kinase activities, reductions in PI4P generation due to
loss of function mutations affecting one of the isozymes
can be sufficient to cause neurological disease.
Mutations of the PI4KA activating protein FAM126A
(hyccin) result in a 10% to 20% decrease in total cellular
PI4P and are associated with a familial leukodystrophy con-
dition featuring hypomyelination and congenital cataract.11
Interestingly, mutations in PI4KA leading to loss of catalytic
activity cause structural brain abnormalities including per-
isylvian polymicrogyria and cerebellar hypoplasia.12
These insights suggest that reduced PI4P generation
can be deleterious for the structural development of the
CNS, but also that diminished PI 4-kinase activity results
in different, mutation-specific, clinical presentations.
Multiple lines of evidence suggest that alterations in
PI4K2A expression can cause disease.
Gene trap Pi4k2a knockout mice exhibit delayed
onset neurodegeneration. Mice homozygous for a Pi4k2a
gene trap allele develop normally and appear normal as
young adults, but exhibit an age-related neu-
rodegeneration phenotype, consisting of tremor, spastic
paraplegia and urinary incontinence.13
In terms of human disease, changes in PI4K2A expres-
sion, possibly due to gene copy number variations, have
been reported in breast cancer14,15 and advanced glioblas-
toma.16 Recently two siblings, with complete loss of func-
tion of PI4K2A, leading to intellectual disability, epilepsy,
myoclonus and akathisia, have been described.17
2 | CLINICAL DESCRIPTION
The female patient was born as the fifth and youngest
child of non-consanguineous and healthy Malay parents.
Pregnancy and delivery were uncomplicated. Features
noted at the age of 12 months included microcephaly,
marked hypotonia in an infant with poor muscle volume,
wasting of subcutaneous fat and hepatomegaly. Develop-
ment was globally delayed, with marked intellectual dis-
ability. Biochemical evaluations revealed lactic acidemia,
4.2 mmol/L (normal 0-2.4), ALAT 94 U/L (normal 0-29),
ASAT 260 U/L (normal 0-36), total bilirubin 38 μmol/L
(normal 0-17), AP 230 U/L (normal 0-341); yGT 328 U/L
(normal 11-50) and elevation of serum alpha-fetoprotein.
Her serum albumin, uric acid, ammonia, creatine kinase
and blood indices were normal. Plasma amino acid anal-
ysis showed raised alanine, 606 μmol/L (normal 148-475)
and mildly elevated methionine, 52 μmol/L (normal
5-34). Urine organic acid analysis showed lactaciduria
and presence of phenyl-derivatives indicating liver
impairment.
Dysmorphic features were noted including a mild
progeroid appearance with high forehead, large ears,
sparse scalp hair, strabismus, hypertelorism, epicanthal
folds, blue sclera, flat nasal bridge, bulbous nose, long,
prominent philtrum and a high palate (Figure 2). Cutis
laxa was displayed with loose and inelastic skin. She had
increased laxity of her joints and choreoathetosis with
continuous involuntary movements of her limbs and
facial musculature. Cerebral MRI revealed delayed cere-
bral myelination and corpus callosum dysplasia. Her liver
function stabilised, and she made slow developmental
progress and is now stable at the age of 12 years. Mild
lactic acidaemia has persisted, however OXPHOS com-
plex measurements in fibroblasts revealed no decreased
enzyme activities or decreased ATP production. mtDNA
depletion in fibroblasts was excluded. Transferrin and
apolipoprotein CIII isoelectric focusing showed normal
N- and O-glycosylation of proteins.
During a physical evaluation at the age of 6 years
old the patient demonstrated almost continuous move-
ments of the face and upper extremities. Large ampli-
tude, almost ballistic, movements at the pelvic girdle,
and to a lesser degree at the shoulder girdle were noted.
In addition, there was frequent facial grimacing with
irregular opening of the mouth, partial protrusions of
the tongue, opening and closing of the eyes and eleva-
tion of the eyebrows. There was posturing of the hands
whereby the patient exhibited abduction and adduction
of the wrists with a tendency to flex at the wrist, hyper-
extend at the metacarpophalangeal joints and to flex at
the interphalangeal joints in a continuously changing
pattern. The feet are intermittently assuming a posture
of inversion and flexion of the feet with writhing move-
ments of the toes. The patient demonstrated hyperex-
tension at the elbows and the spine when she sits up
and then assumes a partially prone position, with
hyperabduction of the hips. There is swaying of the
trunk from side to side. There is also intermittent
esotropia bilaterally. The findings are consistent with
generalised choreoathetosis, associated with joint
hypermobility and hypotonia.
Her neurological phenotype remains the same as at
the age of 6 years old and she is in stable condition. Mild
lactic acidemia has persisted, however OXPHOS complex
measurements in fibroblasts revealed no decreased
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enzyme activities or decreased ATP production. mtDNA
depletion in fibroblasts was excluded. Transferrin and
apolipoprotein CIII isoelectric focusing showed normal
N- and O-glycosylation of proteins.
3 | HISTOLOGY
Elastica-van Gieson (EVG) staining of a skin biopsy rev-
ealed almost absent elastin in the papillary dermis and
fragmented elastin was visualised in the reticular dermis,
confirming the diagnosis of cutis laxa in patient 1 (not
shown).
4 | METHODS
See Supporting Information files.
5 | RESULTS
5.1 | Genetic data
Exome sequencing of DNA obtained from the index
patient was performed and provided 6.3 Gb of mapped
sequencing data, resulting in a median coverage of the
exome of 71.5-fold with at least 20-fold coverage for
78.3% of the exome. Standard variant filtering resulted in
233 rare, non-synonymous and canonical splice site vari-
ants of high quality. From these 233 variants, we selected
the candidate gene variants filtering for gene function,
nucleotide conservation and bi-allelic presence (both
homozygous and compound heterozygous). This resulted
in two genetic variants, of 39 potential variants that were
highly conserved (PhyloP>3.5) in PI4K2A and TWNK
(PEO1, TWINKLE, C10orf2 or TWINKLE mtDNA heli-
case) based on gene function. A homozygous missense
FIGURE 2 Clinical phenotype of the patient at the age of 6 years old. A, The patient, due to severe hypotonia, is unable to sit up
without assistance. B and C, The choreoathetoid movement disorder in combination with hypotonia. D, Several dysmorphic features
including a high forehead, hypertelorism, a prominent philtrum, bitemporal narrowing, hypoplastic bridge of the nose, up-turning nose,
long philtrum, thin upper lip, prominent jaw, prominent ears and strabismus
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mutation was found in PI4K2A, located on chromosome
10. The 823C>T mutation at genomic position 99 416 632
resulted in a R275W amino acid change. For TWNK, also
located on chromosome 10, a homozygous missense
mutation 1306G>C was found, leading to a G436R amino
acid change at position 102 749 463.
The corresponding proteins are known to play a
role in metabolic pathways. The variants in these two
genes co-segregated with disease within the family.
According to in silico prediction programmes such as
SIFT, PolyPhen and MutationTaster, the identified var-
iants were predicted to be ‘deleterious’, ‘probably dam-
aging’ and ‘disease causing’, respectively. Both variants
have not been reported in public databases. Both genes
have no constraint for missense variants in the
GnomAD. Additional assessment of 40 ethnically mat-
ched controls showed that both variants were not
present.
Additional analysis of PI4K2A and TWNK in
27 patients with cutis laxa and a neurological phenotype
revealed no pathogenic variants.
6 | FUNCTIONAL STUDIES
6.1 | PI4P protein levels
Since decreased PI4P generation could potentially arise
due to decreased expression of the PI4K2A enzyme in
patient cells, we used Western blotting to compare pro-
tein levels in patient vs control cells. We found that
PI4K2A expression was not decreased in the patient
fibroblasts compared to controls. Instead, the enzyme
appeared upregulated when the data were corrected for
the loading control, calnexin (Figure 3B).
6.2 | Effects of the R275W mutation on
PI 4-kinase activity
To determine whether the R275W mutation impaired
PI4K2A function, we measured PI 4-kinase activity in
homogenates prepared from control and patient fibro-
blasts using our previously established radiometric assay
that reports the generation of radiolabelled 32P-PI4P by
this isozyme.18 PI4P generation was found to be reduced
by 77.5 ± 0.5% in patient fibroblasts vs control cells
(Figure 3A).
6.3 | Effects of the PI4K2A mutation on
phosphoinositide levels
The large reduction in PI 4-kinase activity in patient cells
prompted us to investigate whether there were any con-
sequences for cellular phosphoinositide levels, as previ-
ous RNAi studies had indicated that PI4K2A activity
maintains approximately 10% to 20% of the total cellular
PI4P pool.19 To this end, HPLC-coupled to mass spec-
trometry was employed to separate and quantify the dif-
ferent acyl chain variants of PI, PIP, PIP2 and PI(3,4,5)P3
in control and patient cells (Figure 4). This approach rev-
ealed that in patient cells the level of the PI4K2A lipid
substrate PI was not decreased implying that any reduc-
tion in catalytic activity was not due to a generalised
depletion of the enzyme's lipid substrate (Figure 4A).
FIGURE 3 PI 4-kinase activity measurement in whole cell homogenates prepared from patient fibroblasts. A, Analysis of the catalytic
activity of PI4K2A shows that cellular PI4P synthesis is inhibited (**P < .01, n = 3) by 78% in patient cells that express only PI4K2A
(R275W). B, Western blots demonstrating that PI4K2A expression is not reduced in patient cells that express the PI4K2A (R275W) variant.
Calnexin is used as a protein loading control. The experiment was repeated 3 times with similar results
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Results for PIP, which predominately reports PI4P and,
to a lesser degree, the much rarer monophosphorylated
PI3P and PI5P lipids,20 revealed that the 18:0/20:4 and
18:1/18:1 PIP species were reduced in patient fibroblasts
by 21% and 17%, respectively and unexpectedly that there
was a 32% increase in the very minor 18:0/20:2 PIP pool
(Figure 4B,C).
It should be noted though that the mean 21%
decrease in 18:0/20:4 PIP was not found to be statistically
significant using the unpaired Student's t-test when the
significance threshold was set at P ≤ 0.05. These results
indicate that loss of PI4K2A activity only affects particu-
lar molecular pools of PI4P (Figure 4B). Extending this
approach to the downstream lipid PIP2 which mainly
reports PI(4,5)P2, revealed a greater impact of the R275W
PI4K2A mutation with a 34% reduction in 18:0/20:4 PIP2
and a 38% decrease in 18:1/18:1 PIP2 (Figure 4C). Finally,
mass spectrometric analysis of the quantitatively rare but
functionally important phosphoinositide PI(3,4,5)P3
showed little overall change in patient cells except for the
18:0/20:3 structural pool that exhibited a marked 93%
increase (Figure 4D).
6.4 | Predicted effects of mutations on
protein structure
We studied the effect of the R275W mutation using the
crystal structure of the catalytic domain of PI4K2A. R275
is located on the surface of the protein, where it directly
interacts with the membrane. Supporting Information
Figure S1 shows the position of this residue in the
octameric complex. Baumlova et al suggested that this
arginine is responsible for electrostatic interactions with
the lipid headgroups.21 The R275W mutation, converting
arginine into tryptophan, leads to an amino acid with a
much larger hydrophobic, but electrostatically neutral
amino acid sidechain (Supporting Information
Figure S1). Therefore, we predict that mutation R275W
will affect membrane anchoring of the PI4K2A protein.
6.5 | Complexome profiling
To assess the effect of the mutations in PI4K2A and a
possible involvement of TWNK, whole cells and
FIGURE 4 HPLC-coupled mass spec analysis of different acyl chain inositol phospholipid species from control and patient cells. Mass
levels of A, PI; B, PIP; C, PIP2 and D, PIP3 were measured. Data are presented as the mean ± SEM of triplicate determinations, *P ≤ .05
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mitochondria enriched fractions from patient and control
fibroblasts were analysed by complexome profiling.22
Complexome profiling enables the investigation of (sub)
complex abundance and composition of protein
complexes.
To examine whether the mutation in TWNK results
in a decreased abundance or an impaired assembly of
OXPHOS complexes, mitochondria enriched fractions
from patient and control fibroblasts were analysed.
Supporting Information Figure S2A shows a heat map
representation of the individual migration patterns of all
OXPHOS complex subunits identified by complexome
profiling. To compare the overall migration pattern of the
different complexes, the average abundance profile of all
subunits was plotted (Supporting Information
Figure S2B). In the experiment shown in Supporting
Information Figure S2B, the nuclear encoded subunits
SDHC and SDHD gave rise to an additional peak in the
complex II profile, we did not observe this subassembly
in the complexome profile obtained from whole cells (not
shown). In patient mitochondria, the abundance and
composition of OXPHOS complexes and supercomplexes
comprising mitochondrially encoded subunits was not
significantly different from that of the control indicating
that the mutation in TWNK had no significant effect on
mitochondrial protein biosynthesis, at least in fibroblast.
6.6 | TGN-lysosome trafficking of GBA
Given the potential abnormalities of the lysosomal
β-glucosidase GBA during PI4K2A deficiency, we studied
in detail the enzyme in the patient's fibroblasts by a vari-
ety of methods.
We examined GBA protein by Western blot analysis
using a specific monoclonal antibody.23 No difference
between GBA in patient and control fibroblast were
revealed (Supporting Information Figure S3), both show-
ing low (58 kDa) molecular weight species known to
coincide with GBA maturation in lysosomes.24,25 Next we
measured total GBA activity in wildtype and patient
fibroblasts. The levels of activity towards
4-methylumbelliferyl-β-glucoside were comparable:
318 ± 18 nmol/h/mg and 327 ± 16 nmol hydrolysis/h/
mg protein in patient and wildtype fibroblasts,
respectively.
Finally, we employed activity-based probes (ABPs)
consisting of a cyclophellitol β-epoxide extended with a
BODIPY fluorophore.26 The ABPs specifically and irre-
versibly label the nucleophile (glutamate 340) of GBA.
They are cell-permeable and allow the labelling of active
GBA molecules in intact cells, which can subsequently be
visualised by SDS-PAGE and fluorescence scanning.26
Patient and control fibroblasts were incubated with
ABP-BODIPY-Red to allow labelling of the enzyme in the
cells. Next, cells were lysed and the lysate was incubated
with ABP-BODIPY-Green to label any unreacted GBA.
No abnormalities in GBA labelled fibroblast, in cells or in
cell lysates, were detected (Supporting Information
Figure S3). Finally, we looked for abnormalities in
glucosylsphingosine, the sphingoid base formed from
glucosylceramide during GBA deficiency in Gaucher dis-
ease. No excessive glucosylsphingosine was detected in
the patient fibroblasts (not shown), suggesting that the
cells contain sufficient functional GBA to degrade
glucosylceramide.
7 | DISCUSSION AND
CONCLUSIONS
The genetic elucidation of novel metabolic cutis laxa syn-
dromes, although recently aided by next generation
sequencing, still proves to be a challenge. Analysis of the
variants can be complicated and, in most cases, more
than one candidate gene was identified. Elaborate func-
tional studies are then needed to assess the pathogenicity
of the different variants. In the patient analysed here,
homozygous and compound heterozygous missense
mutations were found that were predicted to be patho-
genic. Study of the cellular function lead to prioritisation
of two variants.
The pathogenicity of the R275W mutation in PI4K2A
evidently resulted from a 78% reduction in enzyme activ-
ity and the decrease of particular acyl species of PI4P and
PI(4,5)P2 (Figure 3). Moreover, we demonstrate that this
decrease in PI4K2A enzyme activity in patient fibroblasts
was not due to PI substrate depletion or reduced enzyme
expression (Figure 4). Our results are in concordance
with the cellular studies conducted by Zhou et al27 and
Baumlova et al21 where point substitution mutations of
R275 caused an approximately 80% reduction in the
kinase activity of PI4K2A. Our results are comparable to
those reported from Pi4k2a knockout mice, where loss of
the enzyme resulted in >95% decrease in total activity in
fibroblasts and >95% decrease in brain membrane
associated-activity.13 These mice showed a movement
disorder, severe wasting of subcutaneous fat and no
decrease in elastic fibres in skin. Moreover, the percent-
age decreases in the steady state cellular levels of PIP and
PIP2 that we observed are of a similar magnitude as those
previously determined in RNAi studies where PI4K2A
expression was ablated in cultured cells.19 Therefore, our
biochemical analyses demonstrate that the R275W muta-
tion inhibits the lipid kinase activity of PI4K2A. Recently
published descriptions of the PI4K2A crystal structure
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revealed that the positively charged R275 residue is situ-
ated outside the catalytic substrate binding pocket and on
a surface region of the enzyme, which is involved in
maintaining tight association with anionic membrane
lipids.21 Substitution of arginine by a bulky and non-
polar tryptophan residue is predicted to inhibit non-
covalent interactions of the enzyme surface with anionic
membrane lipids, thus providing a molecular mechanism
to explain the marked reduction in PI4K2A activity in
the patient cells. Hence, R275 plays a key role in promot-
ing PI4K2A catalytic activity by sustaining electrostatic
interactions between the enzyme and anionic lipids at
the protein-membrane interface.
We found that levels of PI(3,4,5)P3, a molecule with
potent anti-apoptotic, pro-proliferative and pro-motility
properties, were not reduced in the patient cells. This is
consistent with previous work established that cellular
levels of PI(4,5)P2 do not substrate-limit the generation of
the quantitatively minor lipid PI(3,4,5)P3 (<0.02% of the
total phosphoinositide content in this study) by pho-
sphoinositide 3-kinases. Furthermore, as PI4K2A activity
is required for the endosomal trafficking and degradation
of activated receptor kinases,28 it is conceivable that aug-
mented PI(3,4,5)P3 production could arise indirectly
through decreased degradative trafficking of activated
receptor tyrosine kinases and sustained activation of pho-
sphoinositide 3-kinases. Indeed we found a small but sta-
tistically significant increase in the very low abundance
(0.68 ± 0.03 ng/mg protein) PI(3,4,5)P3 species with
18.0/20:3 of acyl chain composition. The functional sig-
nificance of this alteration to acyl composition is not yet
clear, although it is interesting to note that there is some
evidence that a switch in phosphoinositide acylation pat-
terns can occur in disease as has been shown for some
cancer cell lines with p53 tumour suppressor deletions.29
Our Western blotting results demonstrated that levels
of PI4K2A protein were elevated in patient cells vs con-
trols (Figure 3). This finding indicated that there is a
functional link between the catalytic activity of the
enzyme and its turnover or expression. Interestingly,
work from Mössinger and colleagues revealed that
PI4K2A binds the ubiquitin ligase ITCH through a spe-
cific N-terminal PPxY motif resulting in ubiquitination of
PI4K2A and concomitant PI4K2A-mediated ITCH activa-
tion.30 Since the ITCH binding motif of PI4K2A is unaf-
fected by the R275W mutation, it seems plausible that in
patient cells, PI4K2A is ubiquitinated but nevertheless
subject to delayed degradation due to diminished PI4P-
dependent endo-lysosomal trafficking.28 Further work
will be required to investigate the possibility that dys-
functional protein degradation results from the R275W
mutation and to find out, whether this could affect the
patient neurological phenotype.
Another possible disease mechanism to consider is
that the cutis laxa and neurological phenotype of the
patient may be an indirect consequence of altered
PI4K2A activity on the vacuolar ATPase (V-ATPase). This
endosomal proton pump was found to be dysfunctional
in related conditions31 and may be regulated by PI(3,5)
P2.
32-34 However, given that the production of PI(3,5)P2
does not require PI 4-kinase activity,35,36 V-ATPase
involvement seems unlikely. Trans-Golgi network-
lysosomal trafficking remained unaffected by the R275W
mutation (Supporting Information Figure S2). In addition
to ruling out a general problem with dysfunctional traf-
ficking, these results make it unlikely that the patient's
choreoathetosis is caused by a sphingolipid storage defect
similar to the one implicated in Gaucher's–associated
Parkinson disease (reviewed by Brockmann and Berg37).
Homozygous TWNK mutations are known to cause a
mitochondrial DNA depletion syndrome type 7 (hepa-
tocerebral type) (OMIM 271245). This progressive, neuro-
degenerative syndrome is characterised by hypotonia,
ataxia, opthalmoplegia, hearing loss and seizures leading to
early lethality in most cases.38 We could not exclude that
the clinical phenotype of our patient was partly due to the
TWNK mutations. However, we found no mtDNA deple-
tion in the fibroblasts of our patient and OXPHOS complex
activities were normal. In addition, complexome profiling
analysis showed no evidence for a disturbed biogenesis of
the OXPHOS complexes comprising subunits encoded by
the mitochondrial DNA. Recently the same mutation in
TWNK has been described in a patient with ovarian dys-
genesis, deafness, neuropathy, ataxia and mild intellectual
disability with normal lactate levels,39 these features are
very similar to Perrault syndrome patients with other
reported Twinkle mutations (OMIM 616138).40 No func-
tional evidence for the pathogenicity of these mutations
was provided. Our patient shows no signs of ovarian dys-
genesis and deafness. However, ovarian dysgenesis typi-
cally becomes evident only during puberty while the age of
onset for hearing loss is variable. The next few years it
should become evident whether or not a Perrault-like syn-
drome will also manifest in our patient, who is now
12 years of age. Cutis laxa has never been described in
patients with TWNKmutations, making it unlikely that the
cutis laxa in our patient relates to mutations in this gene.
The male siblings described by Alkhater et al17 pres-
ented with subtle facial dysmorphism at birth, but
showed a normal development till the age of 5 to
6 months. From that age global developmental delay,
dystonia, visual inattentiveness and loss of acquired skills
were noted. They showed a marked movement disorder
characterised by facial dyskinesias and global akathisia
and were, and still are, unable to speak or walk. From
the age of 9 years old both children had epilepsy. There
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was no cutis laxa reported in these patients. A homozy-
gous nonsense mutation in PI4K2A was identified in both
siblings (99400564C>A, c.65C>A; p.Ser22*). It is to be
expected that the biochemical consequence of the homo-
zygous nonsense mutation, a stop codon is introduced
after 22 amino acids leading to a complete loss of func-
tion of PI4K2A, would be more severe than in our
patient. However, the overlap in phenotype is evident.
The knockout mouse model also shows a movement
disorder starting from the age of 4 months.13
In conclusion, our combined observations suggest a dis-
ease mechanism involving dyshomeostasis of particular acyl
chain phosphoinositide subsets on endosomal membranes.
Based on the presentation in our patient, the patients
described by Alkhater et al17 and the previously
characterised mice model we define a novel metabolic
defect in the phosphatidylinositol pathway, presenting
with a severe neurologic phenotype and expanding the
existing phenotype with cutis laxa. Further work is
needed to investigate how this might be relevant to the
patient's clinical presentation.
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